|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5630 EUR | -0.53% |
|
-12.03% | -58.72% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 10/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 5.2Cr | - | - | - | - | |
| 31TCr | |||||
| 6.66TCr | |||||
| 932.3Cr | |||||
| 853.49Cr | |||||
| 410.39Cr |
- Stock Market
- Stocks
- AB Stock
- A8D Stock
- Charts AB Science
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
